[HTML][HTML] Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer …
PD Brown, S Krishnan, JN Sarkaria, W Wu… - Journal of Clinical …, 2008 - ncbi.nlm.nih.gov
PD Brown, S Krishnan, JN Sarkaria, W Wu, KA Jaeckle, JH Uhm, FJ Geoffroy, R Arusell…
Journal of Clinical Oncology, 2008•ncbi.nlm.nih.govPurpose Epidermal growth factor receptor (EGFR) amplification in glioblastoma multiforme
(GBM) is a common occurrence and is associated with treatment resistance. Erlotinib, a
selective EGFR inhibitor, was combined with temozolomide (TMZ) and radiotherapy (RT) in
a phase I/II trial.
(GBM) is a common occurrence and is associated with treatment resistance. Erlotinib, a
selective EGFR inhibitor, was combined with temozolomide (TMZ) and radiotherapy (RT) in
a phase I/II trial.
Abstract
Purpose
Epidermal growth factor receptor (EGFR) amplification in glioblastoma multiforme (GBM) is a common occurrence and is associated with treatment resistance. Erlotinib, a selective EGFR inhibitor, was combined with temozolomide (TMZ) and radiotherapy (RT) in a phase I/II trial.
ncbi.nlm.nih.gov